The global burden of cancer attributable to risk factors, 2010–19: a systematic analysis for the Global Burden of Disease Study 2019

BACKGROUND: Understanding the magnitude of cancer burden attributable to potentially modifiable risk factors is crucial for development of effective prevention and mitigation strategies. We analysed results from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2019 to inform cancer control planning efforts globally. METHODS: The GBD 2019 comparative risk assessment framework was used to estimate cancer burden attributable to behavioural, environmental and occupational, and metabolic risk factors. A total of 82 risk–outcome pairs were included on the basis of the World Cancer Research Fund criteria. Estimated cancer deaths and disability-adjusted life-years (DALYs) in 2019 and change in these measures between 2010 and 2019 are presented. FINDINGS: Globally, in 2019, the risk factors included in this analysis accounted for 4·45 million (95% uncertainty interval 4·01–4·94) deaths and 105 million (95·0–116) DALYs for both sexes combined, representing 44·4% (41·3–48·4) of all cancer deaths and 42·0% (39·1–45·6) of all DALYs. There were 2·88 million (2·60–3·18) risk-attributable cancer deaths in males (50·6% [47·8–54·1] of all male cancer deaths) and 1·58 million (1·36–1·84) risk-attributable cancer deaths in females (36·3% [32·5–41·3] of all female cancer deaths). The leading risk factors at the most detailed level globally for risk-attributable cancer deaths and DALYs in 2019 for both sexes combined were smoking, followed by alcohol use and high BMI. Risk-attributable cancer burden varied by world region and Socio-demographic Index (SDI), with smoking, unsafe sex, and alcohol use being the three leading risk factors for risk-attributable cancer DALYs in low SDI locations in 2019, whereas DALYs in high SDI locations mirrored the top three global risk factor rankings. From 2010 to 2019, global risk-attributable cancer deaths increased by 20·4% (12·6–28·4) and DALYs by 16·8% (8·8–25·0), with the greatest percentage increase in metabolic risks (34·7% [27·9–42·8] and 33·3% [25·8–42·0]). INTERPRETATION: The leading risk factors contributing to global cancer burden in 2019 were behavioural, whereas metabolic risk factors saw the largest increases between 2010 and 2019. Reducing exposure to these modifiable risk factors would decrease cancer mortality and DALY rates worldwide, and policies should be tailored appropriately to local cancer risk factor burden

Design, Synthesis And Biological Evaluation Of Hybrid Bioisoster Derivatives Of N-acylhydrazone And Furoxan Groups With Potential And Selective Anti-trypanosoma Cruzi Activity

Hybrid bioisoster derivatives from N-acylhydrazones and furoxan groups were designed with the objective of obtaining at least a dual mechanism of action: cruzain inhibition and nitric oxide (NO) releasing activity. Fifteen designed compounds were synthesized varying the substitution in N-acylhydrazone and in furoxan group as well. They had its anti-Trypanosoma cruzi activity in amastigotes forms, NO releasing potential and inhibitory cruzain activity evaluated. The two most active compounds (6, 14) both in the parasite amastigotes and in the enzyme contain the nitro group in para position of the aromatic ring. The permeability screening in Caco-2 cell and cytotoxicity assay in human cells were performed for those most active compounds and both showed to be less cytotoxic than the reference drug, benznidazole. Compound 6 was the most promising, since besides activity it showed good permeability and selectivity index, higher than the reference drug. Thereby the compound 6 was considered as a possible candidate for additional studies. © 2014 Elsevier Masson SAS. All rights reserved.82418425Coura, J.R., Dias, J.C.P., Epidemiology, control and surveillance of Chagas disease - 100 years after its discovery (2009) Mem. Inst. Oswaldo Cruz, 104, pp. 31-40Anis, R.J., Anis, R., Marin-Neto, J.A., Chagas disease (2010) Lancet, 375, pp. 1388-1402(2013), http://www.who.int/mediacentre/factsheets/fs340/en/index.html, World Health Organization, WHOGascon, J., Bern, C., Pinazo, M.J., Chagas disease in Spain, the United States and other non-endemic countries (2010) Acta Trop., 115, pp. 22-27Nunes, M.C.P., Dones, W., Montillo, C.A., Encina, J.J., Ribeiro, A.L., Chagas disease: An overview of clinical and epidemiological aspects (2013) J. A. Coll. Cardiol., 62, pp. 767-776Dias, L.C., Dessoy, M.A., Silva, J.N.S., Thiemann, O.H., Oliva, G., Andricopulo, A.D., Quimioterapia da doença de Chagas: Estado da arte e perspectivas no desenvolvimento de novos fármacos (2009) Quim. Nova, 32, pp. 2444-2457Alves, R.M., Thomaz, R.P., Almeida, E.A., Wanderley, J.S., Guariento, M.E., Chagas disease and egeing: The coexistence of other chronic disease with Chagas disease in elderly patients (2009) Rev. Soc. Bras. Med. Trop., 42, pp. 622-628Barreiro, E.J., Fraga, C.A.M., (2008) Química Medicinal: As Bases Moleculares da Ação Dos Fármacos, pp. 271-277. , second ed. Artmed Porto Alegre 343-345Lima, L.M., Barreiro, E.J., Bioisosterism: A useful strategy for molecular modification and drug design (2005) Curr. Med. Chem., 12, pp. 23-49Viegas-Junior, C., Danuello, A., Bolzani, V.S., Barreiro, E.J., Fraga, C.A.M., Molecular hybridization: A useful tool in the design of new drug prototypes (2007) Curr. Med. Chem., 14, pp. 1829-1852Serafim, R.A.M., Primi, M.C., Trossini, G.H.G., Ferreira, E.I., Nitric oxide: State of the art in drug design (2012) Curr. Med. Chem., 19, pp. 385-405Cerecetto, H., González, M., Anti-T. Cruzi agents: Our experience in the evaluation of more than five hundred compounds (2008) Mini-Rev. Med. Chem., 8, pp. 1355-1383Silva, J.J.N., Guedes, P.M.M., Zottis, A., Balliano, T.L., Silva, F.O.N., Lopes, L.G.F., Ellena, J., Silva, J.S., Novel ruthenium complexesas potential drugs for Chagas's disease: Enzyme inhibition and in vitro/in vivo trypanocidal activity (2010) Br. J. Pharmacol., 160, pp. 260-269Brunet, L.R., Nitric oxide in parasitic infections (2001) Int. Immunopharmacol., 1, pp. 1457-1467Romeiro, N.C., Aguirre, G., Hernandez, P., Gomzalez, M., Cerecetto, H., Aldana, I., Perez-Silanes, S., Lima, L.M., Synthesis, trypanocidal activity and docking studies of novel quinaxoline-N-acylhydrazones, designed as cruzain inhibitors candidates (2009) Bioorg. Med. Chem., 17, pp. 641-652Moreira, D.R.M., Leite, A.C.L., Santos, R.R., Soares, M.B.P., Approaches for the development of new anti-Trypanosoma cruzi agents (2009) Curr. Drugs Targets, 10, pp. 212-231McGrath, M.E., Eakin, A.E., Engel, J.C., McKerrow, J.H., Craik, C.S., Fletterick, R.J., The crystal structure of cruzain: A therapeutic target for Chagas' disease (1995) J. Mol. Biol., 247, pp. 251-259Judice, W.A.S., Cezari, M.H.S., Lima, A.P.C.A., Scharfstein, J., Chagas, J.R., Tersariol, I.L.S., Juliano, M.A., Juliano, L., Comparison of the specificity, stability and individual rate constants with respective activation parameters for the peptidase activity of cruzipain and its recombinant form, cruzain, from Trypanosoma cruzi (2001) Eur. J. Biochem., 268, pp. 6578-6586Wilkinson, S.R., Bot, C., Kelly, J.M., Hall, B.S., Trypanocidal activity of nitroaromatic prodrugs: Current treatments and future perspectives (2011) Curr. Med. Chem., 11, pp. 2072-2084(1998) MarvinView 5.4.0. - Free License, , ChemAxon LtdHernandez, P., Rojas, R., Gilman, R.H., Sauvain, M., Lima, L.M., Barreiro, E.J., Gonzalez, M., Cerecetto, H., Hybrid furoxanyl N-acylhydrazone derivatives as hits for the development of neglected diseases drug candidates (2013) Eur. J. Med. Chem., 59, pp. 64-74Storpirtis, S., Gonçalves, J.E., Chiann, C., Gai, M.N., Biofarmacotécnica-série ciências farmacêuticas (2009) Guanab. Koogan, pp. 204-211Souza, J., Benet, L.Z., Huang, Y., Storpirtis, S., Comparison of bidirectional Lamavudine and Zidovudine transport using MDCK, MDCK-MDR1, and Caco-2 cell monolayers (2009) J. Pharm. Sci., 98, pp. 4413-4419Chavda, H.V., Patel, C.N., Anand, I.S., Biopharmaceutical classification system (2010) Syst. Rev. Pharm., 1, pp. 62-69Huber, P.C., Maruiama, C.H., Almeida, W.P., Glicoproteína-P, resistência a múltiplas drogas (MDR) e relação estrutura-atividade de moduladores (2010) Quim. Nova, 33, pp. 2148-2154Fruttero, R., Ferrarotti, B., Serafino, A., Stiloa, D., Gasco, A., Unsummetrically substituted furoxans, Part 11, methylfuroxancarbaldehydes (1989) J. Heterocycl. Chem., 26, pp. 1345-1347Gasco, A.M., Fruttero, R., Sorba, G., Gasco, A., Unsymmetrically substituted furoxans, Part XIII, phenylfuroxancarbaldehydes and related compounds (1991) Liebigs Ann. Chem., pp. 1211-1213Braman, R.S., Hendrix, S.A., Nanogram nitrite and nitrate determination in enviromental and biological materials by vanadium(III) reduction with chemiluminescence detection (1989) Anal. Chem., 61, pp. 2715-2718Castegnaro, (1978) Food Addit. Contam., 4, pp. 37-43Eakin, A.E., Mills, A.A., Harth, G., McKerrow, J.H., Craik, C.S., The sequence, organization, and expression of the major cysteine protease (cruzain) from Trypanosoma cruzi (1992) J. Biol. Chem., 267, pp. 7411-7420Li, R., Kenyon, G.L., Cohen, F.E., Chen, X., Gong, B., Dominguez, J.N., Davidson, E., McKerrow, J.H., In vitro antimalarial activity of chacones and their derivatives (1995) J. Med. Chem., 38, pp. 5031-5037Borchardt, D.M., Mascarello, A., Chiaradia, L.D., Nunes, R.J., Oliva, G., Yunes, R.A., Andricopulo, A.D., Biochemical evaluation of a series of synthetic chalcone and hydrazide derivatives as novel inhibitors of cruzain from Trypanosoma cruzi (2010) J. Braz. Chem. Soc., 21, pp. 142-150Gonçalves, J.E., Fernandes, M.B., Chiann, C., Gai, M.N., Souza, J., Storpirtis, S., Effect of pH, mucin and bovine serum on rifampicin permeability through Caco-2 cells (2012) Biopharm. Drug. Dispos., 33, pp. 316-32

Probability of major depression classification based on the SCID, CIDI, and MINI diagnostic interviews: A synthesis of three individual participant data meta-analyses

Introduction: Three previous individual participant data meta-analyses (IPDMAs) reported that, compared to the Structured Clinical Interview for the DSM (SCID), alternative reference standards, primarily the Composite International Diagnostic Interview (CIDI) and the Mini International Neuropsychiatric Interview (MINI), tended to misclassify major depression status, when controlling for depression symptom severity. However, there was an important lack of precision in the results. Objective: To compare the odds of the major depression classification based on the SCID, CIDI, and MINI. Methods: We included and standardized data from 3 IPDMA databases. For each IPDMA, separately, we fitted binomial generalized linear mixed models to compare the adjusted odds ratios (aORs) of major depression classification, controlling for symptom severity and characteristics of participants, and the interaction between interview and symptom severity. Next, we synthesized results using a DerSimonian-Laird random-effects meta-analysis. Results: In total, 69,405 participants (7,574 [11%] with major depression) from 212 studies were included. Controlling for symptom severity and participant characteristics, the MINI (74 studies; 25,749 participants) classified major depression more often than the SCID (108 studies; 21,953 participants; aOR 1.46; 95% confidence interval [CI] 1.11-1.92]). Classification odds for the CIDI (30 studies; 21,703 participants) and the SCID did not differ overall (aOR 1.19; 95% CI 0.79-1.75); however, as screening scores increased, the aOR increased less for the CIDI than the SCID (interaction aOR 0.64; 95% CI 0.52-0.80). Conclusions: Compared to the SCID, the MINI classified major depression more often. The odds of the depression classification with the CIDI increased less as symptom levels increased. Interpretation of research that uses diagnostic interviews to classify depression should consider the interview characteristics. © 202

Cancer Incidence, Mortality, Years of Life Lost, Years Lived with Disability, and Disability-Adjusted Life Years for 29 Cancer Groups from 2010 to 2019: A Systematic Analysis for the Global Burden of Disease Study 2019

Importance: The Global Burden of Diseases, Injuries, and Risk Factors Study 2019 (GBD 2019) provided systematic estimates of incidence, morbidity, and mortality to inform local and international efforts toward reducing cancer burden. Objective: To estimate cancer burden and trends globally for 204 countries and territories and by Sociodemographic Index (SDI) quintiles from 2010 to 2019. Evidence Review: The GBD 2019 estimation methods were used to describe cancer incidence, mortality, years lived with disability, years of life lost, and disability-adjusted life years (DALYs) in 2019 and over the past decade. Estimates are also provided by quintiles of the SDI, a composite measure of educational attainment, income per capita, and total fertility rate for those younger than 25 years. Estimates include 95 uncertainty intervals (UIs). Findings: In 2019, there were an estimated 23.6 million (95 UI, 22.2-24.9 million) new cancer cases (17.2 million when excluding nonmelanoma skin cancer) and 10.0 million (95 UI, 9.36-10.6 million) cancer deaths globally, with an estimated 250 million (235-264 million) DALYs due to cancer. Since 2010, these represented a 26.3 (95 UI, 20.3-32.3) increase in new cases, a 20.9 (95 UI, 14.2-27.6) increase in deaths, and a 16.0 (95 UI, 9.3-22.8) increase in DALYs. Among 22 groups of diseases and injuries in the GBD 2019 study, cancer was second only to cardiovascular diseases for the number of deaths, years of life lost, and DALYs globally in 2019. Cancer burden differed across SDI quintiles. The proportion of years lived with disability that contributed to DALYs increased with SDI, ranging from 1.4 (1.1-1.8) in the low SDI quintile to 5.7 (4.2-7.1) in the high SDI quintile. While the high SDI quintile had the highest number of new cases in 2019, the middle SDI quintile had the highest number of cancer deaths and DALYs. From 2010 to 2019, the largest percentage increase in the numbers of cases and deaths occurred in the low and low-middle SDI quintiles. Conclusions and Relevance: The results of this systematic analysis suggest that the global burden of cancer is substantial and growing, with burden differing by SDI. These results provide comprehensive and comparable estimates that can potentially inform efforts toward equitable cancer control around the world.. © 2021 American Medical Association. All rights reserved

Safety and efficacy of non-steroidal anti-inflammatory drugs to reduce ileus after colorectal surgery

Background: Ileus is common after elective colorectal surgery, and is associated with increased adverse events and prolonged hospital stay. The aim was to assess the role of non-steroidal anti-inflammatory drugs (NSAIDs) for reducing ileus after surgery. Methods: A prospective multicentre cohort study was delivered by an international, student- and trainee-led collaborative group. Adult patients undergoing elective colorectal resection between January and April 2018 were included. The primary outcome was time to gastrointestinal recovery, measured using a composite measure of bowel function and tolerance to oral intake. The impact of NSAIDs was explored using Cox regression analyses, including the results of a centre-specific survey of compliance to enhanced recovery principles. Secondary safety outcomes included anastomotic leak rate and acute kidney injury. Results: A total of 4164 patients were included, with a median age of 68 (i.q.r. 57\u201375) years (54\ub79 per cent men). Some 1153 (27\ub77 per cent) received NSAIDs on postoperative days 1\u20133, of whom 1061 (92\ub70 per cent) received non-selective cyclo-oxygenase inhibitors. After adjustment for baseline differences, the mean time to gastrointestinal recovery did not differ significantly between patients who received NSAIDs and those who did not (4\ub76 versus 4\ub78 days; hazard ratio 1\ub704, 95 per cent c.i. 0\ub796 to 1\ub712; P = 0\ub7360). There were no significant differences in anastomotic leak rate (5\ub74 versus 4\ub76 per cent; P = 0\ub7349) or acute kidney injury (14\ub73 versus 13\ub78 per cent; P = 0\ub7666) between the groups. Significantly fewer patients receiving NSAIDs required strong opioid analgesia (35\ub73 versus 56\ub77 per cent; P < 0\ub7001). Conclusion: NSAIDs did not reduce the time for gastrointestinal recovery after colorectal surgery, but they were safe and associated with reduced postoperative opioid requirement

Safety of hospital discharge before return of bowel function after elective colorectal surgery

Background: Ileus is common after colorectal surgery and is associated with an increased risk of postoperative complications. Identifying features of normal bowel recovery and the appropriateness for hospital discharge is challenging. This study explored the safety of hospital discharge before the return of bowel function. Methods: A prospective, multicentre cohort study was undertaken across an international collaborative network. Adult patients undergoing elective colorectal resection between January and April 2018 were included. The main outcome of interest was readmission to hospital within 30 days of surgery. The impact of discharge timing according to the return of bowel function was explored using multivariable regression analysis. Other outcomes were postoperative complications within 30 days of surgery, measured using the Clavien\u2013Dindo classification system. Results: A total of 3288 patients were included in the analysis, of whom 301 (9\ub72 per cent) were discharged before the return of bowel function. The median duration of hospital stay for patients discharged before and after return of bowel function was 5 (i.q.r. 4\u20137) and 7 (6\u20138) days respectively (P < 0\ub7001). There were no significant differences in rates of readmission between these groups (6\ub76 versus 8\ub70 per cent; P = 0\ub7499), and this remained the case after multivariable adjustment for baseline differences (odds ratio 0\ub790, 95 per cent c.i. 0\ub755 to 1\ub746; P = 0\ub7659). Rates of postoperative complications were also similar in those discharged before versus after return of bowel function (minor: 34\ub77 versus 39\ub75 per cent; major 3\ub73 versus 3\ub74 per cent; P = 0\ub7110). Conclusion: Discharge before return of bowel function after elective colorectal surgery appears to be safe in appropriately selected patients